share_log

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Capital Increase in Genmab as a Result of Employee Warrant Exercise

由于员工认股权行使,Genmab进行了增资。
GlobeNewswire ·  12/03 13:35

Company Announcement

公司公告

COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants.

丹麦哥本哈根; 2024年12月3日 - genmab A/S(纳斯达克: GMAB)将增加其股本10,355股,这是员工认股权行使的后果。

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

增加的股份并未向现有股东或其他人发放优先权。这些股票的认购价格为每股名义丹麦克朗1元的现金价:

554 shares at DKK 962.00,
3,436 shares at DKK 1,025.00,
4,942 shares at DKK 1,032.00,
305 shares at DKK 1,050.00, and
1,118 shares at DKK 1,334.50.

554股,以962.00丹麦克朗(DKK)的价格。
3,436股,以1,025.00丹麦克朗(DKK)的价格。
4,942股以1,032.00丹麦克郎
305股以1,050.00丹麦克郎,和
1,118股以1,334.50丹麦克郎。

Proceeds to the company are approximately DKK 11.0 million. The increase corresponds to approximately 0.02% of the company's share capital.

公司获得的款项大约为1100万丹麦克郎。此增长对应于公司股本约0.02%。

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly.

新股份是普通股份,没有任何特殊权利,可以自由转让。新股份的认购给予了分红和其他与公司相关的权利。新股将在丹麦商业局注册后在纳斯达克哥本哈根上市。资本增加预计将很快完成。

Pursuant to section 32 of the Danish Capital Markets Act No. 198 of February 26, 2024, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 66,187,186 which is made up of 66,187,186 shares of a nominal value of DKK 1 each, corresponding to 66,187,186 votes.

根据丹麦资本市场法案第32条第198号,特此公布,Genmab A/S资本增加后的总名义值为66,187,186丹麦克朗,由66,187,186股占每股1丹麦克朗的名义值组成,相当于66,187,186票。

About Genmab
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines.

Genmab是一家国际生物技术公司,其核心目标是引导其不可阻挡的团队致力于改善患者生活,为此不断创新和研发不同的抗体治疗方法。25年来,其充满激情、创新和协作的团队发明了下一代抗体技术平台,并利用转化、定量和数据科学来推进项目进展,包括双特异性T细胞激动剂、抗体药物联用、下一代免疫检查点调节剂和增强功效功能的抗体。到2030年,Genmab的愿景是利用令人惊叹的抗体药物改善癌症和其他严重疾病患者的生活。
Genmab是一家国际生物技术公司,其核心目标是引导不可阻挡的团队努力改善具有创新性和差异化的抗体治疗药物的患者生活。25年来,Genmab的充满激情、创新和协作的团队发明了下一代抗体技术平台,并利用翻译、定量和数据科学,形成了包括双特异T细胞结合剂、抗体药物联用治疗、下一代免疫检查点调节剂和增强效应功能抗体在内的专有药物流水线。到2030年,Genmab的愿景是通过炫酷的抗体药物(KYSO)改变癌症和其他严重疾病患者的生活。

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.
Contact:
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

联系人:Marisol Peron,高级副总裁,全球通信和企业事务 电话:+1 609 524 0065;电子邮件:mmp@genmab.com Andrew Carlsen,副总裁,投资者关系负责人 电话:+45 3377 9558;电子邮件:acn@genmab.com
联系人:
Marisol Peron,全球通信和企业事务高级副总裁
电话:+1 609 524 0065;电子邮件:mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com
This Company Announcement contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; HexaBody; DuoHexaBody, HexElect and KYSO.

Andrew Carlsen,投资者关系负责人
电话:+45 3377 9558;电子邮件:acn@genmab.com
本公司公告含有前瞻性声明。诸如“相信”、“期望”、“预计”、“计划”和类似表达方式等的措辞标识出前瞻性声明。实际结果或表现可能与此类声明所表述的未来结果或表现存在实质性差异或差异被暗示是此种语言表达。可能导致我们实际结果或表现与此类声明存在实质性不同的重要因素包括:与产品的临床前和临床开发相关的风险;与有关临床试验的结果和进行相关的风险;关于产品制造的不确定性;市场对我们产品的缺乏接受程度;我们无法管理增长;在我们的业务领域和市场中的竞争环境;吸引和留住合适合格人员的能力;我们的专利和专有权的执行能力或缺乏保护;我们与关联实体的关系;可能使我们产品或技术变得过时的技术的变化和发展以及其他因素。对于这些风险的进一步讨论,请参阅Genmab最近的财务报告中的风险管理部分,这些报告可在 上获得,以及包括在Genmab的最近一份20-F年度报告和其他提交给美国证券交易委员会(SEC)的文件中的风险因素,在该www.sec.gov。Genmab不承担更新或修订本公司公告中的前瞻性声明的任何义务,也不确认此类声明是否在证券法义务下随后发生的事件或情况之后或与实际结果相关联。
Genmab A/S及/或其子公司拥有以下商标:Genmab; Y形状的Genmab标志; Genmab结合Y形状的标志; HuMax; DuoBody; HexaBody; DuoHexaBody、HexElect和KYSO。

Company Announcement no. 63
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

公司公告编号63
CVR 编号2102 3884
LEI代码529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

genmab A/S
Carl Jacobsens Vej 30
2500瓦尔比
丹麦

Attachment

附件

  • 031224_CA63_Warrant Exercise
  • 031224_CA63权证行权

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发